<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">russjcardiol</journal-id><journal-title-group><journal-title xml:lang="ru">Российский кардиологический журнал</journal-title><trans-title-group xml:lang="en"><trans-title>Russian Journal of Cardiology</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1560-4071</issn><issn pub-type="epub">2618-7620</issn><publisher><publisher-name>«SILICEA-POLIGRAF» LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.15829/1560-4071-2023-5269</article-id><article-id custom-type="elpub" pub-id-type="custom">russjcardiol-5269</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОСТРАЯ И ХРОНИЧЕСКАЯ И СЕРДЕЧНАЯ НЕДОСТАТОЧНОСТЬ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>ACUTE AND CHRONIC HEART FAILURE. ORIGINAL ARTICLES</subject></subj-group></article-categories><title-group><article-title>Неблагоприятные сердечно-сосудистые события у пациентов с коронарной микроваскулярной дисфункцией: результаты 12-месячного наблюдения с группой контроля</article-title><trans-title-group xml:lang="en"><trans-title>Adverse cardiovascular events in patients with coronary microvascular dysfunction: results of a 12-month follow-up with a control group</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-2285-6438</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Копьева</surname><given-names>К. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Kopyeva</surname><given-names>K. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Копьева Кристина Васильевна — кандидат медицинских наук, научный сотрудник отделения патологии миокарда.</p><p>Томск</p></bio><bio xml:lang="en"><p>Tomsk</p></bio><email xlink:type="simple">kristin-kop@inbox.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-1311-0378</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Мальцева</surname><given-names>А. Н.</given-names></name><name name-style="western" xml:lang="en"><surname>Maltseva</surname><given-names>A. N.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Мальцева Алина Николаевна — аспирант лаборатории радионуклидных методов исследования.</p><p>Томск</p></bio><bio xml:lang="en"><p>Tomsk</p></bio><email xlink:type="simple">maltseva.alina.93@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-0883-466X</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Мочула</surname><given-names>А. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Mochula</surname><given-names>A. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Мочула Андрей Викторович — кандидат медицинских наук, старший научный сотрудник лаборатории радионуклидных методов исследования.</p><p>Томск</p></bio><bio xml:lang="en"><p>Tomsk</p></bio><email xlink:type="simple">mochula.andrew@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-4019-3735</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Гракова</surname><given-names>Е. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Grakova</surname><given-names>E. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Гракова Елена Викторовна — доктор медицинских наук, ведущий научный сотрудник отделения патологии миокарда.</p><p>Томск</p></bio><bio xml:lang="en"><p>Tomsk</p></bio><email xlink:type="simple">vgelen1970@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-1513-8614</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Завадовский</surname><given-names>К. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Zavadovsky</surname><given-names>K. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Завадовский Константин Валерьевич — доктор медицинских наук, заведующий отделом лучевой диагностики.</p><p>Томск</p></bio><bio xml:lang="en"><p>Tomsk</p></bio><email xlink:type="simple">konstzav@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Научно-исследовательский институт кардиологии, Томский национальный исследовательский медицинский центр Российской академии наук</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Cardiology Research Institute, Tomsk National Research Medical Center</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2023</year></pub-date><pub-date pub-type="epub"><day>15</day><month>04</month><year>2023</year></pub-date><volume>28</volume><issue>3</issue><fpage>5269</fpage><lpage>5269</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Копьева К.В., Мальцева А.Н., Мочула А.В., Гракова Е.В., Завадовский К.В., 2023</copyright-statement><copyright-year>2023</copyright-year><copyright-holder xml:lang="ru">Копьева К.В., Мальцева А.Н., Мочула А.В., Гракова Е.В., Завадовский К.В.</copyright-holder><copyright-holder xml:lang="en">Kopyeva K.V., Maltseva A.N., Mochula A.V., Grakova E.V., Zavadovsky K.V.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://russjcardiol.elpub.ru/jour/article/view/5269">https://russjcardiol.elpub.ru/jour/article/view/5269</self-uri><abstract><sec><title>Цель</title><p>Цель. Оценить развитие неблагоприятных сердечно-сосудистых событий у пациентов с необструктивным поражением коронарных артерий (КА) и коронарной микроваскулярной дисфункцией (КМД), выявленной по данным динамической однофотонной эмиссионной томографии (ОФЭКТ) миокарда, в течение 12 мес. наблюдения, в сравнении с пациентами без КМД.</p></sec><sec><title>Материал и методы</title><p>Материал и методы. В исследование включено 118 пациентов (70 мужчин, средний возраст 62,0 (58,0; 69,0) лет) с сохраненной фракцией выброса левого желудочка (62 (59; 64)%) и необструктивным поражением КА. Оценку сывороточных уровней N-концевого промозгового натрийуретического пептида выполняли исходно с помощью иммуноферментного анализа. Резерв коронарного кровотока (CFR) оценивали по данным динамической ОФЭКТ. CFR ≤2 являлся маркером КМД.</p></sec><sec><title>Результаты</title><p>Результаты. Шесть пациентов выбыли из исследования по причине утери контакта с ними, остальные были разделены на группы в зависимости от наличия КМД: группа 1 включала больных с КМД (CFR ≤2; n=42), а группа 2 составила группу контроля и включала больных без КМД (CFR &gt;2; n=70). В течение 12 мес. наблюдения у 25 пациентов зарегистрированы неблагоприятные события. По результатам анализа по Каплану-Майеру выявлено, у пациентов с КМД частота неблагоприятных сердечно-сосудистых событий была выше (45,2%, n=19), чем у пациентов без нее (8,6%, n=6) (p&lt;0,001). По данным многофакторного регрессионного анализа наличие КМД (отношение шансов (ОШ) 2,42; 95% доверительный интервал (ДИ): 1,26-5,85; p&lt;0,001) и диастолической дисфункции (ДД) (ОШ 3,27; 95% ДИ: 2,26-5,64; p&lt;0,001) являлись независимыми предикторами неблагоприятных исходов. Сочетание КМД с ДД более чем в 5 раз увеличивало риск неблагоприятных событий (ОШ 5,18; 95% ДИ: 3,61-11,84; p&lt;0,001).</p></sec><sec><title>Заключение</title><p>Заключение. Установлено, что у пациентов с необструктивным поражением КА наличие КМД, выявленной по данным динамической ОФЭКТ миокарда, было связано с более высоким риском развития неблагоприятных сердечно-сосудистых событий в течение 12-мес. периода наблюдения, чем у пациентов без КМД. При этом сочетание КМД с ДД более чем в 5 раз увеличивало риск неблагоприятных исходов.</p></sec></abstract><trans-abstract xml:lang="en"><sec><title>Aim</title><p>Aim. To assess the development of adverse cardiovascular events in patients with non-obstructive coronary artery disease (CAD) and coronary microvascular dysfunction (CMD), identified by dynamic myocardial single-photon emission computed tomography (SPECT), during 12-month follow-up compared with patients without CMD.</p></sec><sec><title>Material and methods</title><p>Material and methods. The study included 118 patients (70 men, mean age, 62,0 [58,0; 69,0] years) with preserved ejection fraction (62 [59; 64] %) and non-obstructive CAD. Serum levels of the N-terminal pro-brain natriuretic peptide were assessed at baseline by enzyme immunoassay. Coronary flow reserve (CFR) was assessed by dynamic SPECT. CFR ≤2 was a CMD marker.</p></sec><sec><title>Results</title><p>Results. Six patients discontinued participation in the study due to loss of contact with them, while the rest were divided into groups depending on CMD presence: group 1 included patients with CMD (CFR ≤2; n=42), and group 2 was the control group and included patients without CMD (CFR &gt;2; n=70). Within 12-month follow-up, 25 patients reported adverse events. According to Kaplan-Meier analysis, the prevalence of adverse cardiovascular events was higher in patients with CMD (45,2%, n=19) than in patients without it (8,6%, n=6) (p&lt;0,001). Multivariate regression analysis showed that the presence of CMD (odds ratio (OR), 2,42; 95% confidence interval (CI), 1,26-5,85; p&lt;0,001) and diastolic dysfunction (OR, 3,27; 95% CI, 2,26-5,64; p&lt;0,001) were independent predictors of poor outcomes. The combination of CMD with diastolic dysfunction more than 5 times increased the risk of adverse events (OR, 5,18; 95% CI, 3,61-11,84; p&lt;0,001).</p></sec><sec><title>Conclusion</title><p>Conclusion. We found that in patients with non-obstructive CAD, the presence of CMD, identified by dynamic myocardial SPECT, was associated with a higher risk of adverse cardiovascular events within 12-month follow-up period than in patients without CMD. At the same time, the combination of CMD with diastolic dysfunction more than 5 times increased the risk of adverse outcomes.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>сердечная недостаточность</kwd><kwd>сохраненная фракция выброса</kwd><kwd>коронарная микроваскулярная дисфункция</kwd><kwd>прогноз</kwd><kwd>резерв коронарного кровотока</kwd></kwd-group><kwd-group xml:lang="en"><kwd>heart failure</kwd><kwd>preserved ejection fraction</kwd><kwd>coronary microvascular dysfunction</kwd><kwd>prognosis</kwd><kwd>coronary blood flow reserve</kwd></kwd-group><funding-group><funding-statement xml:lang="ru">Грант Президента Российской Федерации № MK-4257.2022.3.</funding-statement><funding-statement xml:lang="en">Grant of the President of the Russian Federation No. MK-4257.2022.3.</funding-statement></funding-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) With the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2021;42(36):3599-726. doi:10.1093/eurheartj/ehab368.</mixed-citation><mixed-citation xml:lang="en">McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) With the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2021;42(36):3599-726. doi:10.1093/eurheartj/ehab368.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Wintrich J, Kindermann I, Ukena C, et al. Therapeutic approaches in heart failure with preserved ejection fraction: past, present, and future. Clin Res Cardiol. 2021;109:1079-98. doi:10.1007/s00392-020-01633-w.</mixed-citation><mixed-citation xml:lang="en">Wintrich J, Kindermann I, Ukena C, et al. Therapeutic approaches in heart failure with preserved ejection fraction: past, present, and future. Clin Res Cardiol. 2021;109:1079-98. doi:10.1007/s00392-020-01633-w.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">D’Amario D, Migliaro S, Borovac JA, et al. Microvascular Dysfunction in Heart Failure With Preserved Ejection Fraction. Front Physiol. 2019;10:1347. doi:10.3389/fphys.2019.01347.</mixed-citation><mixed-citation xml:lang="en">D’Amario D, Migliaro S, Borovac JA, et al. Microvascular Dysfunction in Heart Failure With Preserved Ejection Fraction. Front Physiol. 2019;10:1347. doi:10.3389/fphys.2019.01347.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Мочула А. В., Копьева К. В., Мальцева А. Н. и др. Резерв коронарного кровотока у пациентов с хронической сердечной недостаточностью с сохраненной фракцией выброса левого желудочка. Российский кардиологический журнал. 2022;27(2):4743. doi:10.15829/1560-4071-2022-4743.</mixed-citation><mixed-citation xml:lang="en">Mochula AV, Kop’eva KV, Maltseva AN, et al. Coronary flow reserve in patients with heart failure with preserved ejection fraction. Russian Journal of Cardiology. 2022;27(2):4743. (In Russ.) doi:10.15829/1560-4071-2022-4743.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Taqueti VR, Di Carli MF. Clinical significance of noninvasive coronary flow reserve assessment in patients with ischemic heart disease. Curr Opin Cardiol. 2016;31(6):662-9. doi:10.1097/HCO.0000000000000339.</mixed-citation><mixed-citation xml:lang="en">Taqueti VR, Di Carli MF. Clinical significance of noninvasive coronary flow reserve assessment in patients with ischemic heart disease. Curr Opin Cardiol. 2016;31(6):662-9. doi:10.1097/HCO.0000000000000339.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Driessen RS, Raijmakers PG, Stuijfzand WJ, Knaapen P. Myocardial perfusion imaging with PET. Int J Cardiovasc Imaging. 2017;33:1021-31. doi:10.1007/s10554-017-1084-4.</mixed-citation><mixed-citation xml:lang="en">Driessen RS, Raijmakers PG, Stuijfzand WJ, Knaapen P. Myocardial perfusion imaging with PET. Int J Cardiovasc Imaging. 2017;33:1021-31. doi:10.1007/s10554-017-1084-4.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Nagueh SF, Smiseth OA, Appleton CP. Recommendations for the evaluation of left ventricular diastolic function by echocardiography: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging. 2016;17:1321-60. doi:10.1016/j.echo.2016.01.011.</mixed-citation><mixed-citation xml:lang="en">Nagueh SF, Smiseth OA, Appleton CP. Recommendations for the evaluation of left ventricular diastolic function by echocardiography: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging. 2016;17:1321-60. doi:10.1016/j.echo.2016.01.011.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Austen WG, Edwards JE, Frye RL, et al. A reporting system on patients evaluated for coronary artery disease. Report of the Ad Hoc Committee for Grading of Coronary Artery Disease, Council on Cardiovascular Surgery, American Heart Association. Circulation. 1975;51:5-40. doi:10.1161/01.cir.51.4.5.</mixed-citation><mixed-citation xml:lang="en">Austen WG, Edwards JE, Frye RL, et al. A reporting system on patients evaluated for coronary artery disease. Report of the Ad Hoc Committee for Grading of Coronary Artery Disease, Council on Cardiovascular Surgery, American Heart Association. Circulation. 1975;51:5-40. doi:10.1161/01.cir.51.4.5.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Murthy VL, Naya M, Taqueti VR, et al. Effects of sex on coronary microvascular dysfunction and cardiac outcomes. Circulation. 2014;129:2518-27. doi:10.1161/CIRCULATIONAHA.113.008507.</mixed-citation><mixed-citation xml:lang="en">Murthy VL, Naya M, Taqueti VR, et al. Effects of sex on coronary microvascular dysfunction and cardiac outcomes. Circulation. 2014;129:2518-27. doi:10.1161/CIRCULATIONAHA.113.008507.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Mileva N, Nagumo S, Mizukami T, et al. Prevalence of Coronary Microvascular Disease and Coronary Vasospasm in Patients With Nonobstructive Coronary Artery Disease: Systematic Review and Meta‐Analysis. Journal of the American Heart Association. 2022;11:e023207. doi:10.1161/JAHA.121.023207.</mixed-citation><mixed-citation xml:lang="en">Mileva N, Nagumo S, Mizukami T, et al. Prevalence of Coronary Microvascular Disease and Coronary Vasospasm in Patients With Nonobstructive Coronary Artery Disease: Systematic Review and Meta‐Analysis. Journal of the American Heart Association. 2022;11:e023207. doi:10.1161/JAHA.121.023207.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Shimokawa H, Suda A, Takahashi J, et al. Clinical characteristics and prognosis of patients with microvascular angina: an international and prospective cohort study by the Coronary Vasomotor Disorders International Study (COVADIS) Group. Eur Heart J. 2021;42(44):4592-600. doi:10.1093/eurheartj/ehab282.</mixed-citation><mixed-citation xml:lang="en">Shimokawa H, Suda A, Takahashi J, et al. Clinical characteristics and prognosis of patients with microvascular angina: an international and prospective cohort study by the Coronary Vasomotor Disorders International Study (COVADIS) Group. Eur Heart J. 2021;42(44):4592-600. doi:10.1093/eurheartj/ehab282.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Schroder J, Michelsen MM, Mygind ND, et al. Coronary flow velocity reserve predicts adverse prognosis in women with angina and no obstructive coronary artery disease: results from the iPOWER study. Eur Heart J. 2021;42(3):228-39. doi:10.1093/eurheartj/ehaa944.</mixed-citation><mixed-citation xml:lang="en">Schroder J, Michelsen MM, Mygind ND, et al. Coronary flow velocity reserve predicts adverse prognosis in women with angina and no obstructive coronary artery disease: results from the iPOWER study. Eur Heart J. 2021;42(3):228-39. doi:10.1093/eurheartj/ehaa944.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Kato S, Fukui K, Kodama S, et al. Cardiovascular magnetic resonance assessment of coronary flow reserve improves risk stratification in heart failure with preserved ejection fraction. J Cardiovasc Magn Reson. 2021;23;112. doi:10.1186/s12968-021-00807-3.</mixed-citation><mixed-citation xml:lang="en">Kato S, Fukui K, Kodama S, et al. Cardiovascular magnetic resonance assessment of coronary flow reserve improves risk stratification in heart failure with preserved ejection fraction. J Cardiovasc Magn Reson. 2021;23;112. doi:10.1186/s12968-021-00807-3.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Filali Y, Kesäniemi A, Ukkola O. Soluble ST2, a biomarker of fibrosis, is associated with multiple risk factors, chronic diseases and total mortality in the OPERA study. Scand J Clin Lab Invest. 2021;81(4):324-31. doi:10.1080/00365513.2021.1904518.</mixed-citation><mixed-citation xml:lang="en">Filali Y, Kesäniemi A, Ukkola O. Soluble ST2, a biomarker of fibrosis, is associated with multiple risk factors, chronic diseases and total mortality in the OPERA study. Scand J Clin Lab Invest. 2021;81(4):324-31. doi:10.1080/00365513.2021.1904518.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Zavadovsky KV, Mochula AV, Boshchenko AA, et al. Absolute myocardial blood flows derived by dynamic CZT scan vs invasive fractional flow reserve: correlation and accuracy. J Nucl Cardiol. 2021;28:1:249-59. doi:10.1007/s12350-019-01678-z.</mixed-citation><mixed-citation xml:lang="en">Zavadovsky KV, Mochula AV, Boshchenko AA, et al. Absolute myocardial blood flows derived by dynamic CZT scan vs invasive fractional flow reserve: correlation and accuracy. J Nucl Cardiol. 2021;28:1:249-59. doi:10.1007/s12350-019-01678-z.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
